2.5000 -0.04 (-1.57%)
After hours: 6:17PM EDT
|Bid||2.5300 x 4000|
|Ask||2.6000 x 36200|
|Day's Range||2.5300 - 2.7100|
|52 Week Range||1.5400 - 3.8800|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
If you want to know who really controls Agenus Inc. (NASDAQ:AGEN), then you'll have to look at the makeup of its share...
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
MARIETTA, Ga., May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm.
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...
- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long ter...
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells. The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer. Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1. "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day.
LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020. Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.